Adamas Pharmaceuticals has patented a method for reducing OFF time in Parkinson’s disease patients using extended-release amantadine. The method involves administering specific doses of amantadine compositions orally once daily. This innovation aims to alleviate sleep disturbances in patients undergoing amantadine treatment. GlobalData’s report on Adamas Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Adamas Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Adamas Pharmaceuticals, was a key innovation area identified from patents. Adamas Pharmaceuticals's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Extended release amantadine for reducing sleep disturbances in parkinson's disease

Source: United States Patent and Trademark Office (USPTO). Credit: Adamas Pharmaceuticals Inc

A recently granted patent (Publication Number: US11903908B2) outlines a method for reducing OFF time in patients with Parkinson's disease who are being treated with levodopa and experiencing OFF periods. The method involves orally administering a first composition containing 85 mg to 170 mg of a pharmaceutically acceptable salt of amantadine, followed by a second composition with about 300 mg to 380 mg of the same salt. The second composition is designed for extended release, and after at least 7 weeks of daily administration, a reduction in OFF time is observed. Importantly, the plasma concentration of amantadine in the patient increases by less than 10% at 1 hour post-administration of the second composition.

Furthermore, the patent details specific dosages, timing of administration, and pharmacokinetic parameters for optimal results. The method aims to increase ON time without troublesome dyskinesia, with a specific ratio of increased ON time to decreased OFF time. The reduction in OFF time is determined through a placebo-controlled, double-blind clinical study, where the total daily amount of OFF time is reduced by 10% to 40% compared to placebo. The compositions are formulated to provide extended release and specific plasma concentration profiles, ensuring steady-state levels for effective management of Parkinson's symptoms. Overall, the method offers a targeted approach to improving treatment outcomes for patients with Parkinson's disease experiencing OFF periods while on levodopa therapy.

To know more about GlobalData’s detailed insights on Adamas Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies